Log in to save to my catalogue

Heterogeneity of Alzheimer's disease: consequence for drug trials?

Heterogeneity of Alzheimer's disease: consequence for drug trials?

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_cbdccb5cb4da4fd18f20b444c28584c7

Heterogeneity of Alzheimer's disease: consequence for drug trials?

About this item

Full title

Heterogeneity of Alzheimer's disease: consequence for drug trials?

Publisher

England: BioMed Central Ltd

Journal title

Alzheimer's research & therapy, 2018-12, Vol.10 (1), p.122-122, Article 122

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Alzheimer's disease is a heterogenous disorder with multiple phenotypes and genotypes, although they eventually converge to a final common clinicopathological endpoint. However, Alzheimer's disease drug trials do not account for the heterogeneity of the disease in trial design, impeding development of effective drugs.
Alzheimer's disease drug tr...

Alternative Titles

Full title

Heterogeneity of Alzheimer's disease: consequence for drug trials?

Authors, Artists and Contributors

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_cbdccb5cb4da4fd18f20b444c28584c7

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_cbdccb5cb4da4fd18f20b444c28584c7

Other Identifiers

ISSN

1758-9193

E-ISSN

1758-9193

DOI

10.1186/s13195-018-0455-y

How to access this item